Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy.

Brown ES, Tirado C, Minhajuddin A, Hillhouse M, Adinoff B, Ling W, Doraimani G, Thomas C.

J Ethn Subst Abuse. 2010;9(2):106-14. doi: 10.1080/15332641003772587.

2.

Effects of ethnicity on low-dose opiate stabilization.

Kosten TR, Rayford BS.

J Subst Abuse Treat. 1995 Mar-Apr;12(2):111-6.

PMID:
7623388
3.

Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence.

Ziedonis DM, Amass L, Steinberg M, Woody G, Krejci J, Annon JJ, Cohen AJ, Waite-O'Brien N, Stine SM, McCarty D, Reid MS, Brown LS Jr, Maslansky R, Winhusen T, Babcock D, Brigham G, Muir J, Orr D, Buchan BJ, Horton T, Ling W.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):28-36. doi: 10.1016/j.drugalcdep.2008.06.016. Epub 2008 Sep 20.

4.

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience.

Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T.

Am J Addict. 2004;13 Suppl 1:S42-66.

5.

Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.

Chakrabarti A, Woody GE, Griffin ML, Subramaniam G, Weiss RD.

Drug Alcohol Depend. 2010 Mar 1;107(2-3):253-6. doi: 10.1016/j.drugalcdep.2009.10.014. Epub 2009 Nov 30.

6.

Tobacco Withdrawal Amongst African American, Hispanic, and White Smokers.

Bello MS, Pang RD, Cropsey KL, Zvolensky MJ, Reitzel LR, Huh J, Leventhal AM.

Nicotine Tob Res. 2016 Jun;18(6):1479-87. doi: 10.1093/ntr/ntv231. Epub 2015 Oct 18.

PMID:
26482061
7.

Comparison of behavioral treatment conditions in buprenorphine maintenance.

Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J.

Addiction. 2013 Oct;108(10):1788-98. doi: 10.1111/add.12266. Epub 2013 Jul 12.

8.

Racial/Ethnic Differences in Self-reported Withdrawal Symptoms and Quitting Smoking Three Years Later: A Prospective, Longitudinal Examination of US Adults.

Weinberger AH, Platt JM, Smith PH, Goodwin RD.

Nicotine Tob Res. 2017 Mar 1;19(3):373-378. doi: 10.1093/ntr/ntw221.

PMID:
27613908
9.

From research to the real world: buprenorphine in the decade of the Clinical Trials Network.

Ling W, Jacobs P, Hillhouse M, Hasson A, Thomas C, Freese T, Sparenborg S, McCarty D, Weiss R, Saxon A, Cohen A, Straus M, Brigham G, Liu D, McLaughlin P, Tai B.

J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S53-60. doi: 10.1016/j.jsat.2010.01.009.

10.

Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model.

Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, Weiss RD, Trivedi M.

Addict Behav. 2015 Feb;41:20-8. doi: 10.1016/j.addbeh.2014.09.021. Epub 2014 Sep 28.

11.

Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.

Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.

Arch Intern Med. 2011 Mar 14;171(5):425-31. doi: 10.1001/archinternmed.2010.541.

13.

Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM.

Drug Alcohol Depend. 2011 Nov 1;118(2-3):326-34. doi: 10.1016/j.drugalcdep.2011.04.013. Epub 2011 May 19.

14.

Participant characteristics and buprenorphine dose.

Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W.

Am J Drug Alcohol Abuse. 2011 Sep;37(5):453-9. doi: 10.3109/00952990.2011.596974.

15.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002025. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD002025.

PMID:
15495026
16.

A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.

Amass L, Pukeleviciene V, Subata E, Almeida AR, Pieri MC, D'Egidio P, Stankova Z, Costa A, Smyth BP, Sakoman S, Wei Y, Strang J.

Addiction. 2012 Jan;107(1):142-51. doi: 10.1111/j.1360-0443.2011.03577.x. Epub 2011 Oct 12.

PMID:
21749526
17.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2000;(3):CD002025. Review. Update in: Cochrane Database Syst Rev. 2002;(2):CD002025.

PMID:
10908521
19.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD002025. Review. Update in: Cochrane Database Syst Rev. 2009;(3):CD002025.

PMID:
16625553
20.

Buprenorphine for the management of opioid withdrawal.

Gowing L, Ali R, White J.

Cochrane Database Syst Rev. 2002;(2):CD002025. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD002025.

PMID:
12076434

Supplemental Content

Support Center